6.5 C
New York
Saturday, June 12, 2021

Whooping Cough Vaccine Reduces Risk Of Dementia by 42 Percent – Says Study

Must Read

Aakash Molpariya
Aakash started in Nov 2018 as a writer at Revyuh.com. Since joining, as writer, he is mainly responsible for Software, Science, programming, system administration and the Technology ecosystem, but due to his versatility he is used for everything possible. He writes about topics ranging from AI to hardware to games, stands in front of and behind the camera, creates creative product images and much more. He is a trained IT systems engineer and has studied computer science. By the way, he is enthusiastic about his own small projects in game development, hardware-handicraft, digital art, gaming and music. Email: aakash (at) revyuh (dot) com

A growing number of studies have revealed that adult vaccinations are associated with a lower risk of dementia. In a study, researchers have found that tetanus, diphtheria, pertussis (whooping cough) vaccination might lower dementia risk by 42%.

Adult vaccinations may help reduce the risk for dementia. However, it has not been established whether tetanus, diphtheria, pertussis (Tdap) vaccination is associated with incident dementia.

Therefore, Dr. Jeffrey F Scherrer and his team conducted a study to determine whether individuals with an objective history of Tdap vaccination, compared to those remaining free of Tdap vaccination, had lower dementia incidence.

They further evaluated whether this association differed by age groups (65–69, 70–74, and ≥75 years).

Researchers tested their hypothesis first in the Veterans Health Affairs (VHA) cohort and then replicated it in an IBM MarketScan medical claims cohort. The representative cohort study used deidentified VHA medical record data from 2008-2019.

The MarketScan cohort was comprised of de-identified patient data from 2009-2018. The cohorts included patients who had at least three well-visits during the observation period. Follow-up continued through 2018. They included a total of 122,946 eligible VHA patients and 174,053 eligible MarketScan patients.

In the VHA cohort, the patients were, on average, 75.6 (SD ± 7.5) years of age, 4% female, and 91.2% were White. In the MarketScan cohort, the patients were 69.8 (SD ± 5.6) years of age and 65.4% were female. They used Competing risk (VHA) and Cox proportional hazard (MarketScan) models to assess the association between Tdap vaccination and incident dementia in all patients and age subgroups.

Key findings of the study were:

The researchers found that after controlling for confounding variables, patients with Tdap vaccination had a significantly lower risk for dementia in both groups. (VHA: hazard ratio [HR] = 0.58 and MarketScan: HR = 0.58).

The authors concluded:

Tdap vaccination was associated with a 42% lower dementia risk in 2 cohorts with different clinical and sociodemographic characteristics. Several vaccine types are linked to decreased dementia risk, suggesting that these associations are due to nonspecific effects on inflammation rather than vaccine-induced pathogen-specific protective effects.

The study findings were published in The Journals of Gerontology: Series A on April 15, 2021.

Image Credit: iStock

- Advertisement -
- Advertisement -

Latest News

FDA forces Johnson & Johnson to scrap 60 million doses of its COVID vaccine

The US Food and Drug Administration (FDA) ordered the Johnson & Johnson company to discard 60 million doses of...
- Advertisement -

More Articles Like This

- Advertisement -